Articles - Page 2 of 10 - Tumori Journal

Sequential therapy of metastatic urothelial cancer with monomethyl auristatin E (MMAE)-containing antibody-drug conjugates for different targets

Case ReportBy giuliat September 29, 2025

Antibody-drug conjugate (ADC) has become the standard of treatment for metastatic urothelial cancer. Current trials generally test the combination or sequential use of antibody-drug conjugates with different targets and different chemotherapeutic reagents.
We show that in three patients with metastatic urothelial cancer who have progressed on anti-HER2 antibody-drug conjugates, two showed responses when treated with EV (the same monomethyl auristatin E-containing ADC, but with different targets).

Details

Comparison of breast cancer surgery cases in urban and rural areas: Clinical factors and patient-reported outcomes

Research ArticleBy giuliat September 29, 2025

This study aimed to evaluate regional disparities in surgical approaches and patient-reported outcomes (PROs) among early breast cancer patients in urban and rural areas of Nagasaki Prefecture, Japan.
We retrospectively analyzed clinicopathological data from 1032 patients (urban: 818; rural: 214) who underwent breast cancer surgery between 2014 and 2021. PROs were assessed using the BREAST-Q survey conducted from October 2022 to June 2024 among patients; a total of 76 patients (urban n = 40; rural n = 36) completed the questionnaire.

Details

Mantle cell lymphoma with hypereosinophilia: A case report and review of the literature

Case ReportBy giuliat September 20, 2025

Reactive eosinophilia has been reported in several hematological malignancies, including Hodgkin–s lymphoma, T-cell lymphoma/leukemia, and acute leukemia. However, eosinophilia associated with B-cell non-Hodgkin–s lymphoma is rarely reported. Mantle cell lymphoma is a subcategory of non-Hodgkin–s lymphoma originated from mature B cells. In this article, we report for the first time a case of mantle cell lymphoma with hypereosinophilia.

Details

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives

EditorialBy giuliat September 15, 2025

Breast cancer (BC) is the leading cause of cancer-related mortality among women, with early BC (EBC) comprising most cases. Advancements in neo(adjuvant) therapies have significantly improved outcomes, although they are often associated with cancer treatment-induced bone loss, which increases the risk of fractures and negatively impacts quality of life.

Details

Association of APOC1 levels and nutritional indices with clinicopathological features and prognostic value in patients with DLBCL

Research ArticleBy giuliat September 15, 2025

This study aims to unravel the relationship between apolipoprotein C1 (APOC1) levels, prognostic nutritional index (PNI), and clinicopathological characteristics in patients with diffuse large B-cell lymphoma (DLBCL) and their prognostic predictive value.
This study retrospectively analyzed clinical data from 55 DLBCL patients and 50 healthy screening volunteers. APOC1 levels and the PNI were compared between groups, along with their association with DLBCL’s clinicopathological features.

Details

Predicting severe toxicity after head-and-neck cancer RT: Validation of the synergist role of a biological marker and dosimetry

Research ArticleBy giuliat September 15, 2025

To assess the value of biologically enriched Normal Tissue Complication Probability (NTCP) models integrating clinical, dosimetric, and biological markers, specifically the RadioDtect© assay based on phosphorylated ATM (Ataxia-Telangiectasia Mutated, pATM) quantification.
We considered 67 patients with head-and-neck cancer receiving curative-intent radiotherapy. We developed logistic NTCP models for severe acute/late toxicities (grade ⩾3) using (i) the pATM-based RadioDtect test, (ii) clinical-dosimetric variables, and (iii) a combined model.

Details

An indirect approach to identify the healthcare services for thyroid and melanoma cancer patients in Italy: Epicost-2 project

Research ArticleBy giuliat September 4, 2025

An indirect approach was applied to the case-study of thyroid cancer (TC) and melanoma of the skin (MS) in Italy to identify health services (HS) for cancer patients and to enable cost estimation.
Within the Epicost-2 project, a self-controlled crossover design analysed TC and MS 2018 prevalent cases from Italian cancer registries. Controls (1:1) were matched to cases 18-6 months prior to diagnosis; increases between cases and controls in potentially cancer-related HS claims (P⩽5%) were identified.

Details

Delphi Study on the creation of a Committee of patients, caregivers, and representatives of patient associations

Research ArticleBy giuliat August 30, 2025

As part of the improvement plan of the Organisation of European Cancer Institutes at the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan (INT) a Committee composed of patients, caregivers, and representatives of patient associations has been established to actively participate in the planning and organization of both hospital services and research initiatives. The potential impact of implementation of the Committee could ensure a patient-centered care environment.

Details

Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis

Research ArticleBy giuliat August 29, 2025

Despite Immune-Oncology (IO) combinations, bone metastases (BM) remain a clinical challenge, occurring in ~30% of metastatic renal cell carcinoma (mRCC) patients and leading to skeletal-related events (SREs). Bone-targeted therapies (BTT), denosumab (Dmab) and zoledronic acid (ZOL AC), reduce SREs but are associated with a risk of Medication-Related Osteonecrosis of the Jaw (MRONJ), especially when combined with Vascular Endothelial Growth Factor Receptor – Tyrosine Kinase Inhibitors (VEGFR-TKIs).

Details

The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations

Research ArticleBy giuliat August 9, 2025

Women carriers of BRCA1/2 mutations face a very high lifetime risk (penetrance) of developing breast and/or ovarian cancer. A sizeable proportion of carriers, however, does not develop cancer at all or develop it only late in life, thus suggesting a potential modulation of this risk. Epidemiological studies have suggested that other genetic (polymorphisms) and environmental factors (lifestyle) affect penetrance. However, data regarding these associations mainly come from retrospective case-control analyses and the results are likely to be distorted by bias.

Details